Precipio, Inc. (NASDAQ:PRPO) Short Interest Up 19.6% in March

Precipio, Inc. (NASDAQ:PRPO) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 12,800 shares, an increase of 19.6% from the February 28th total of 10,700 shares. Based on an average daily volume of 9,400 shares, the short-interest ratio is presently 1.4 days. Approximately 1.0% of the company’s shares are sold short.

Precipio Trading Down 1.6 %

NASDAQ PRPO traded down $0.09 during trading hours on Wednesday, hitting $5.56. 2,653 shares of the company’s stock were exchanged, compared to its average volume of 7,879. The firm has a market cap of $8.24 million, a price-to-earnings ratio of -3.04 and a beta of 1.37. The stock has a 50-day simple moving average of $7.07 and a 200 day simple moving average of $6.48. The company has a current ratio of 0.73, a quick ratio of 0.60 and a debt-to-equity ratio of 0.02. Precipio has a 1-year low of $4.31 and a 1-year high of $10.74.

Precipio (NASDAQ:PRPO) last announced its quarterly earnings data on Thursday, March 27th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of $0.74 by ($0.97). The company had revenue of $5.45 million for the quarter, compared to analyst estimates of $8.01 million. Precipio had a negative return on equity of 34.01% and a negative net margin of 17.23%.

Hedge Funds Weigh In On Precipio

A hedge fund recently bought a new stake in Precipio stock. Renaissance Technologies LLC acquired a new position in Precipio, Inc. (NASDAQ:PRPO) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,100 shares of the biotechnology company’s stock, valued at approximately $56,000. Renaissance Technologies LLC owned about 0.68% of Precipio as of its most recent SEC filing. Institutional investors and hedge funds own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.